Skin

Yowie Surprises Fans with Ultra Rare Glass Frog Collectible as Part of "Animals with Superpowers" Series

Retrieved on: 
Monday, January 17, 2022 - 10:18am
Giant, Apple, Muscle, NEW, Collection, Google Play, Learning, Instagram, Animal, Skin, Superpower, Glass frog, Child, Social media, Awareness, Toy, Hunting, Yowie, Facebook, Pinterest

Surprise-Inside Confectionery Brand Announces Release of New, Ultra Rare Collectible Figurine

Key Points: 
  • Surprise-Inside Confectionery Brand Announces Release of New, Ultra Rare Collectible Figurine
    NEW YORK, NY, Jan 17, 2022 - (ACN Newswire) - Yowie Group eagerly announces the debut of a new, "ultra" rare collectible, the Pacific Giant Glass Frog.
  • This figurine is the rarest collectible Yowie has ever released and is a part of the newly released "Animals with Superpowers" series.
  • The odds of finding a Pacific Giant Glass Frog are one in one thousand!
  • Information regarding the Pacific Giant Glass Frog is available on Yowie's website so fans can learn more.

Global Guanylate Cyclase Activators Pipeline Market Report 2021 Featuring Novan, Radikal Therapeutics, Ironwood Pharmaceuticals, & Bayer - ResearchAndMarkets.com

Retrieved on: 
Monday, January 17, 2022 - 11:35am
Health, Pharmaceutical, NDA, Guanylate cyclase 2C, Technology, News, Molluscum contagiosum, Clinical trial, Discovery, Activator, Skin infection, Hypertensive emergency, Guanylate cyclase, Skin, Therapy, SB206, GC, II, Administration, Route, Route of administration, Acquisition, Medical imaging, Pharmaceutical industry

This "Guanylate Cyclase (Guanyl Cyclase or Guanylyl Cyclase or GC) Activators - Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Guanylate Cyclase (Guanyl Cyclase or Guanylyl Cyclase or GC) Activators pipeline landscape.

Key Points: 
  • This "Guanylate Cyclase (Guanyl Cyclase or Guanylyl Cyclase or GC) Activators - Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Guanylate Cyclase (Guanyl Cyclase or Guanylyl Cyclase or GC) Activators pipeline landscape.
  • A detailed picture of the Guanylate Cyclase (Guanyl Cyclase or Guanylyl Cyclase or GC) Activators pipeline landscape is provided which includes the disease overview and Guanylate Cyclase (Guanyl Cyclase or Guanylyl Cyclase or GC) Activators treatment guidelines.
  • Guanylate Cyclase (Guanyl Cyclase or Guanylyl Cyclase or GC) Activators: Therapeutic Assessment
    This segment of the report provides insights about the different Guanylate Cyclase (Guanyl Cyclase or Guanylyl Cyclase or GC) Activators drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • Guanylate Cyclase (Guanyl Cyclase or Guanylyl Cyclase or GC) Activators pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Dermavant Presents New Patient Satisfaction Data from PSOARING 3 Long Term Extension Trial of Tapinarof in Adults with Plaque Psoriasis at the 2022 Winter Clinical Dermatology Conference

Retrieved on: 
Saturday, January 15, 2022 - 1:00pm
Health, FDA, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, People, Atopic dermatitis, Ageing, New Drug Application, Roivant Sciences, Patient, Research, Vitiligo, Week, Conference, Acne, Psoriasis, LinkedIn, Dermatitis, Perception, Inflammatory bowel disease, Safety, Adult, PGA, Patient satisfaction, QD, Obesity, Hypertension, Skin, National Psoriasis Foundation, Oslo bid for the 2022 Winter Olympics, Diabetes, Efficiency, Quality of life, Depression, Therapy, Risk, Twitter, FDA, Physician, Pharmaceutical industry, Medical device

These results were presented during the 2022 Winter Clinical Dermatology Conference, held January 14-19 in Koloa, Hawaii.

Key Points: 
  • These results were presented during the 2022 Winter Clinical Dermatology Conference, held January 14-19 in Koloa, Hawaii.
  • Dermavants pivotal Phase 3 clinical program for tapinarof in adult plaque psoriasis consists of PSOARING 1 (NCT03956355) and PSOARING 2 (NCT03983980), as well as PSOARING 3 (NCT04053387), a long-term extension study.
  • PSOARING 3 was a long-term, open-label, extension study to evaluate the safety and efficacy of tapinarof cream, 1% for the treatment of plaque psoriasis in adults.
  • The company has reported positive Phase 3 results for tapinarof cream in adult patients with plaque psoriasis.

U.S. FDA Approves Pfizer’s CIBINQO® (abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitis

Retrieved on: 
Friday, January 14, 2022 - 8:30pm
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Janus, Atopic dermatitis, New Drug Application, NDA, Patient, Food and Drug Administration, Week, Janus kinase 1, Pfizer, Dupilumab, Inc., Psoriasis Area and Severity Index, NYSE, Rash, Common, Adult, Nausea, CEO, JADE, Disease, Kidney failure, CYP2C19, AD, Department, George Washington University School of Medicine & Health Sciences, Headache, PFE, Inflammation, Outline of health sciences, Skin, Pain, JAK1, CYP, MD, Dermatitis, Food, Immunology, FDA, EASI, MPH, IGA, Pharmaceutical industry, P450, Safety, Doctor of Philosophy

Atopic dermatitis is so much more than just a rash, and it goes beyond the surface of the skin.

Key Points: 
  • Atopic dermatitis is so much more than just a rash, and it goes beyond the surface of the skin.
  • We appreciate Pfizers commitment to this resilient patient community and eagerly await the positive impact CIBINQO could have on the treatment landscape for moderate-to-severe atopic dermatitis.
  • Five clinical trials in the CIBINQO JAK1 Atopic Dermatitis Efficacy and Safety (JADE) global development program were included in the New Drug Application (NDA) to support the FDA approval.
  • Atopic dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population.

Felix Biotechnology to Collaborate with AnimalBiome on a Novel Solution for Pet Diarrhea

Retrieved on: 
Friday, January 14, 2022 - 6:17pm
Pernicious, Research, Synthetic biology, Technology, BD, SAN, CSO, Diarrhea, Drug of last resort, Adoption, San Francisco Bay Area, Solution, Biotechnology, Dentistry, Health, PETS, Animal, Bacteria, Skin, Lawrence Berkeley National Laboratory, Felix, Y Combinator, Multimedia, Engineering, Yale University, Partnership, Machine learning, Pharmaceutical industry, Antibiotics, Vaccine

The company has several on-going partnerships to develop phage-based solutions with personal care and cosmetic companies, and this deal expands their footprint into animal health.

Key Points: 
  • The company has several on-going partnerships to develop phage-based solutions with personal care and cosmetic companies, and this deal expands their footprint into animal health.
  • "We are committed to finding a better solution for this common affliction plaguing pets and distressing their owners," says Dr. Natalie Ma, Felix Cofounder and Head of BD at Felix.
  • AnimalBiome markets and sells a spectrum of products addressing digestive, skin, and oral health, from testing to targeted microbiome supplements to restore and maintain pet health.
  • Felix Biotechnology is focused on discovering, developing and deploying customizable antimicrobials targeting urgent microbial threats.

U.S. FDA Approves RINVOQ® (upadacitinib) to Treat Adults and Children 12 Years and Older with Refractory, Moderate to Severe Atopic Dermatitis

Retrieved on: 
Friday, January 14, 2022 - 6:10pm
Atopic dermatitis, Cancer, Giant cell arteritis, Juvenile idiopathic arthritis, Patient, Stroke, Lymphoma, Stomach, Skin cancer, TB, Vein, Allergy, Throat, Virus, Smoker, Psoriasis Area and Severity Index, Enzyme, Degenerative disease, Psoriatic arthritis, AbbVie, Safety, Rash, Scaly, Tears, Death, Surge arrester, Injection, NRS, Human, Disease, Skin, Tongue, Siliceous ooze, TNF, Ulcerative colitis, Time, Bacteria, Artery, Axial spondyloarthritis, Takayasu's arteritis, Infection, Crohn's disease, JAK, Extrapyramidal system, Association, HCP, Dermatitis, Risk, Tell, Rheumatoid arthritis, Shingles, Lung cancer, EASI, Sunlight, Fungus, Tuberculosis, Medical imaging, Synthetic rubber, Pharmaceutical industry, Liquor, Vaccine, Dietary supplement, Birth control, Perfume, Poultry, Copper, Frankincense, Machine tool, EU, Takayasu

RINVOQ is also approved in the EU for adults (15 mg and 30 mg) and adolescents (15 mg) with moderate to severe atopic dermatitis.

Key Points: 
  • RINVOQ is also approved in the EU for adults (15 mg and 30 mg) and adolescents (15 mg) with moderate to severe atopic dermatitis.
  • RINVOQ is safe and effective in children 12 years of age and older weighing at least 88 pounds (40 kg) with atopic dermatitis.
  • It is not known if RINVOQ is safe and effective in children under 12 years of age with atopic dermatitis.
  • If any of these symptoms occur during treatment with RINVOQ, stop taking RINVOQ and get emergency medical help right away.

Novan Announces Presentation of Two Posters at the 2022 Winter Clinical Dermatology Conference

Retrieved on: 
Friday, January 14, 2022 - 2:05pm
Grand Promenade, Forward-looking statement, NDA, Patient, Technology, Skin, Conference, BOTE, Annual report, Safety, Inflammation, NCE, Private Securities Litigation Reform Act, COVID-19, Science, Dermatology, Efficacy, GLOBE, Molluscum contagiosum, New chemical entity, U.S. Securities and Exchange Commission, Novin, Company, Caregiver, US Foods, Risk, SB206, FDA, Security (finance), Sodium, Symptoms of COVID-19, Pharmaceutical industry, Medical device

DURHAM, N.C., Jan. 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (the Company or Novan) (Nasdaq: NOVN), today announced that data from the Companys completed Phase 2 and Phase 3 clinical studies of berdazimer 10.3% gel (previously referred to as SB206) for molluscum contagiosum will be presented at the 2022 Winter Clinical Dermatology Conference, being held January 14-19, 2022, in Koloa, Hawaii.

Key Points: 
  • DURHAM, N.C., Jan. 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (the Company or Novan) (Nasdaq: NOVN), today announced that data from the Companys completed Phase 2 and Phase 3 clinical studies of berdazimer 10.3% gel (previously referred to as SB206) for molluscum contagiosum will be presented at the 2022 Winter Clinical Dermatology Conference, being held January 14-19, 2022, in Koloa, Hawaii.
  • There is currently no US Food & Drug Administration (FDA) approved medication indicated for the treatment of molluscum.
  • The latter represents a clinical sign of inflammation and imminent resolution of molluscum lesions that has never been prospectively studied in a molluscum clinical trial.
  • For more information about the conference, visit: https://fallclinical.health/
    Novan, Inc. is a pre-commercial nitric oxide-based pharmaceutical company focused on dermatology and anti-infective therapies.

BLESSED MOON, Korean Skincare Brand, Expands Into Global Markets With Vitamin Eye Cream ‘Eye Kit’

Retrieved on: 
Friday, January 14, 2022 - 2:00pm
Online Retail, Cosmetics, Retail, Health, Consumer, Women, Other Health, Growth, Vitamin A, Atmosphere, Skin, Vitamin, Generation Z, Sale, Millennials, Woman, Cosmetics, Instagram, MOON

BLESSED MOON (CEO: Eun Bin Moon), a popular skincare brand in Korea, expands into overseas markets with its vitamin eye cream Eye Kit.

Key Points: 
  • BLESSED MOON (CEO: Eun Bin Moon), a popular skincare brand in Korea, expands into overseas markets with its vitamin eye cream Eye Kit.
  • Consisted of an eye cream Eye Kit, a moisture cream Water Kit and a cleansing foam Clean Kit, the flagship Vita Kit line products can sufficiently supply fresh vitamins to skin as they are contained in capsule containers of a new concept that help vitamins less corrupt.
  • Containing 5 different vitamins, including Vitamin A, B, C, E and P, that are good for skin, Eye Kit delivers a super antioxidant effect.
  • Having earned popularity with only customer reviews, Eye Kit is widely recognized in Korea for its compact design and definite effects.

Glenmark Specialty S.A. (Switzerland) receives NDA Approval by the United States Food and Drug Administration (FDA) for Ryaltris™ Nasal Spray for the Treatment of Symptoms of Seasonal Allergic Rhinitis in Adults and Pediatric Patients 12 Years of Age an

Retrieved on: 
Friday, January 14, 2022 - 12:30pm
Medicine, Taste, New Drug Application, Menarini, NDA, Patient, DJSI, Bausch Health, Rhinitis, Czech Republic, Breast milk, OH, Virus, Allergy, Biosimilar, Safety, Health Canada, Dermatology, Review, Nose, Glenmark, United Kingdom, Fungus, Tuberculosis, Skin, Bacteria, Recurrence, Industry, Infection, Index, Olopatadine, Pregnancy, Measles, Risk, Immune system, Corporate sustainability, Dow Jones, FDA, DCP, Physician, Mometasone, Pharmaceutical industry, Fine chemical, Vaccine, Petroleum jelly, Birth control, EU, Olopatadine/mometasone

"With this NDA approval, we look forward to bringing this new medicine to physicians and their patients for the treatment of symptoms of seasonal allergic rhinitis, including nasal and ocular symptoms."

Key Points: 
  • "With this NDA approval, we look forward to bringing this new medicine to physicians and their patients for the treatment of symptoms of seasonal allergic rhinitis, including nasal and ocular symptoms."
  • Ryaltris is a metered, fixed-dose, aqueous suspension, prescription drug product nasal spray approved by the FDA for the treatment of symptoms associated with Seasonal Allergic Rhinitis.
  • The combination drug product nasal spray is indicated for the treatment of symptoms associated with seasonal allergic rhinitis in adults and pediatric patients 12 years of age and older.
  • The safety and effectiveness of Ryaltris in pediatric patients younger than 12 years of age has not been established.

Tattoo Aftercare Products: Assessment of the Global Industry 2021-2028 with Projected Shares for Soothing Balms, Gels, Cleaner Wash, Soap Wash, Foaming Wash, Films, and Other Products - ResearchAndMarkets.com

Retrieved on: 
Friday, January 14, 2022 - 9:57am
Cosmetics, Retail, COVID-19, Industry, Skin, Aftercare, Cosmetics

The "Tattoo Aftercare Products Market Forecast to 2028 - COVID-19 Impact and Global Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Tattoo Aftercare Products Market Forecast to 2028 - COVID-19 Impact and Global Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The global tattoo aftercare products industry is segmented into product and end-user.
  • Based on the product, the market is segmented into soothing balm, gel, cleaner, soap or foaming wash, film, and others.
  • The increasing recommendation for tattoo aftercare products to soften the dry skin after tattoo and make the tattoo look sharp and healthy.